{name}
{subtitle}
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
city
~18 mi. (Castelló de la Plana, Spain, +383 more cities)
facility
Hospital Provincial Castellón
biomarker
ER Negative, +2 more biomarkers
drug
atezolizumab, +4 more drugs
drug type
chemotherapy, +1 more type
A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)
city
~18 mi. (Castelló de la Plana, Spain, +115 more cities)
facility
Hospital Provincial de Castellon; Servicio de Oncologia
biomarker
ERBB2 Amplification, +7 more biomarkers
drug type
immunotherapy, +1 more type
Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients
city
~18 mi. (Castelló de la Plana, Spain, +21 more cities)
facility
Consorcio Hospitalario Provincial de Castellón
biomarker
ER Positive, +2 more biomarkers
drug
abemaciclib, +2 more drugs
drug type
hormone therapy, +1 more type
Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer
city
~18 mi. (Castelló de la Plana, Spain, +13 more cities)
facility
Hospital Provincial de Castellón
biomarker
ER Negative, +2 more biomarkers
drug
capecitabine, +4 more drugs
drug type
chemotherapy, +1 more type
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
city
~36 mi. (Valencia, Spain, +89 more cities)
facility
Fundación Instituto Valenciano de Oncología-Oncologico ( Site 1332)
biomarker
ER Positive, +2 more biomarkers
drug
capecitabine, +4 more drugs
drug type
chemotherapy, +1 more type
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
city
~36 mi. (Valencia, Spain, +226 more cities)
facility
Instituto Valenciano de Oncologia ( Site 0331)
drug
enzalutamide, +1 more drug
drug type
hormone therapy, +1 more type
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
city
~36 mi. (Valencia, Spain, +140 more cities)
facility
Hospital General Universitario de Valencia ( Site 0595)
drug
lenvatinib, +2 more drugs
drug type
chemotherapy, +2 more types
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
city
~36 mi. (Valencia, Spain, +207 more cities)
facility
Hospital Clinico Universitario de Valencia ( Site 1355)
biomarker
ER Positive, +1 more biomarker
drug
cyclophosphamide, +6 more drugs
drug type
chemotherapy, +3 more types
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
city
~36 mi. (Valencia, Spain, +159 more cities)
facility
Instituto Valenciano de Oncologia - IVO ( Site 0662)
drug
cisplatin, +2 more drugs
drug type
chemotherapy, +1 more type
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
city
~36 mi. (Valencia, Spain, +163 more cities)
facility
Instituto Valenciano de Oncologia - IVO ( Site 0679)
drug
cystectomy, +2 more drugs
drug type
chemotherapy, +3 more types